MaxCyte Q3 core revenue up 23% YoY to $8.1M; net loss $11.6M; guidance raised

MAXCYTE, INC.

2024-Q3 EPS reported -$0.29 revenue$29,934,000

Total Q3 revenue $8.2M (+2% YoY); core business revenue $8.1M (+23% YoY) driven by cell therapy growth of 39%.
Net loss of $11.6M vs $11.3M in Q3 2023; EBITDA loss $13.0M; stock-based comp $3.4M.
Signed 6 new SPL clients YTD, including Kamau, Legend Biotech, Be Bio; total SPL partners now 29.
Full-year core revenue guidance raised to at least 5% growth; SPL program revenue affirmed at ~$6M.
Cash and investments $196.6M at Sep 30; expects to end 2024 with ~$185M; evaluating potential AIM listing cancellation.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.